Brexpiprazole laurate suspension as well as preparation method and application thereof
Through the preparation of epipiprazole laurate suspension, combined with ultrasonic stirring and microjet high-pressure homogenization method, the problems of suspension stability and preparation cost in the prior art were solved, and the long-term effect of epipiprazole suspension was realized. Stability and efficient therapeutic effect, suitable as a long-acting injection.
Patent Information
- Application Number
- CN202310602269.6
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2023-05-25
- Publication Date
- 2024-12-03
AI Technical Summary
The existing epipiprazole suspensions have shortcomings in long-term stability and preparation costs, especially the suspension has poor physical and chemical stability, easy degradation and transformation, and the preparation process is complex and expensive, which cannot meet the needs of long-acting injections.
Using epipiprazole laurate suspension, a suspension with excellent pharmacokinetic characteristics was prepared by adding a small amount of auxiliary materials. It was prepared by ultrasonic stirring and microjet high-pressure homogenization method, which avoided the freeze-drying step and simplified the process. The process and improves the stability and safety of the suspension by optimizing the combination of particle stabilizer and buffer salt.
The long-term stability and safety of epipiprazole suspension is achieved, the production cost of the preparation is reduced, the duration of treatment concentration is provided, the adverse reactions of sudden drug release are reduced, and the clinical application value is significantly improved.
Smart Images

Figure CN119055589A_ABST
Abstract
Description
Technical Field
[0001] The invention belongs to the technical field of medicines, and in particular relates to an epirinotecan laurate suspension, a preparation method and application thereof. Background Art
[0002] Brexpiprazole, as shown in Formula II, is commercially available under the name It was jointly developed by Lundbeck of Denmark and Otsuka Pharmaceutical Co., Ltd. of Japan, and was approved by the U.S. Food and Drug Administration (FDA) for marketing on July 10, 2015, for the adjunctive treatment of schizophrenia and major depressive disorder (MDD) in adults. Compared with its analogue aripiprazole, epriprazole has better therapeutic effect and tolerability, and can reduce the incidence of adverse reactions such as akathisia, restlessness and insomnia in patients.
[0003] Therefore, epiridol has emerged as a therapeutic candidate for schizophrenia patients suitable for long-term use.
[0004]
[0005] There is no long-acting formulation of ipirazole on the market yet. Among long-acting injections, ready-to-use aqueous suspensions are the most convenient preparations for clinical use. However, in order to ensure good preparation quality, the suspended particles are required to have good physical and chemical stability to prevent degradation and crystallization in water; the particle size is kept within a usable range and cannot form dense sediments to ensure resuspension after transportation or storage; the compound has extremely low water solubility to prevent the drug "burst release" after injection from causing side effects.
[0006] Patent CN201280043980's Example 22 reports that lauric acid pyrimethamine is a brown oily substance that cannot meet the formulation requirements of an aqueous suspension; Patent CN201380021612 reports suspensions of anhydrous and dihydrate of pyrimethamine, but freeze-drying is an essential step in its preparation process. The preparation technology is complex and expensive, and the problem of long-term stability of the suspension is not fundamentally solved. Summary of the invention
[0007] The technical problem to be solved by the present invention is to improve the long-term stability of the suspension, and to provide an epiriprazole laurate suspension, a preparation method and an application thereof. The epiriprazole laurate suspension only requires a small amount of auxiliary materials to achieve good stability, and has pharmacokinetic characteristics that are completely superior to those of the epiriprazole dihydrate suspension. Moreover, compared with the epiriprazole dihydrate suspension, the epiriprazole laurate suspension has better safety, lower preparation process cost and greater practical use.
[0008] The present invention is achieved through the following technical solutions:
[0009] The present invention provides an epiriprazole laurate suspension, which comprises epiriprazole laurate particles as shown in formula I and water;
[0010]
[0011] The epiriprazole laurate suspension further preferably comprises a particle stabilizer, a buffer salt and an isotonicity regulator.
[0012] The epiriprazole laurate suspension is preferably composed of epiriprazole laurate particles, a particle stabilizer, a buffer salt, an isotonicity regulator and water.
[0013] The epiriprazole laurate particles are preferably epiriprazole laurate amorphous or crystalline forms, more preferably particles of epiriprazole laurate crystal form A. The epiriprazole laurate crystal form A has a powder diffraction (XRPD) pattern with characteristic peaks at diffraction angles (2θ) of 3.7±0.2°, 6.4±0.2°, 11.2±0.2°, 12.7±0.2°, 14.8±0.2°, 15.0±0.2°, 18.5±0.2°, 19.0±0.2°, 19.7±0.2°, 20.2±0.2°, 21.7±0.2°, and 23.4±0.2°.
[0014] The content of the epiriprazole laurate particles is preferably 10-1000 mg / mL, more preferably 50-250 mg / mL, such as 75 mg / mL, 200 mg / mL or 223.45 mg / mL.
[0015] In the epiriprazole laurate suspension, mg / mL is the ratio of the mass of each component in the epiriprazole laurate suspension (excluding water) to the volume of water in the epiriprazole laurate suspension.
[0016] The epiriprazole laurate granules D 10 It is preferably 0.5-5.0 μm, more preferably 0.8-4.0 μm, for example 0.93 μm, 1.0 μm, 1.3 μm, 1.4 μm, 1.5 μm, 2.0 μm or 3.3 μm.
[0017] The epiriprazole laurate granules D 50 It is preferably 1.0-10.0 μm, more preferably 1.5-8.0 μm, for example 1.8 μm, 2.21 μm, 2.5 μm, 3.6 μm, 4.0 μm, 4.1 μm or 6.0 μm.
[0018] The epiriprazole laurate granules D 90 Preferably, it is 2.0-30.0 μm, more preferably 3.0-20.0 μm, for example, 3.1 μm, 4.7 μm, 6.0 μm, 7.0 μm, 10.4 μm, 10.5 μm or 12.2 μm.
[0019] The particle size distribution span of the epiriprazole laurate particles is preferably 0.5-3.0, more preferably 1.0-3.0, such as 1.2, 1.3, 2.3, 2.5 or 2.7.
[0020] The particle stabilizer is preferably one or more of polyethylene glycol, polyvinyl pyrrolidone, poloxamer, hydroxypropyl methylcellulose and Tween. The polyethylene glycol is preferably polyethylene glycol 4000. The poloxamer is preferably poloxamer 188 or poloxamer 407. The hydroxypropyl methylcellulose is preferably hydroxypropyl methylcellulose E3 or hydroxypropyl methylcellulose E5. The Tween is preferably Tween 80 or Tween 20. The particle stabilizer is more preferably Tween 20 and polyethylene glycol 4000, or, poloxamer 188, Tween 20 and polyethylene glycol 4000.
[0021] The content of the particle stabilizer is preferably 10-60 mg / mL, such as 20 mg / mL, 40 mg / mL, 45 mg / mL or 50 mg / mL.
[0022] When the particle stabilizers are Tween 20 and polyethylene glycol 4000, the content of Tween 20 is preferably 5-10 mg / mL; the content of polyethylene glycol 4000 is preferably 15-30 mg / mL.
[0023] When the particle stabilizers are poloxamer 188, Tween 20 and polyethylene glycol 4000, the content of Tween 20 is preferably 5-10 mg / mL; the content of polyethylene glycol 4000 is preferably 15-30 mg / mL; and the content of poloxamer 188 is preferably 10 mg / mL.
[0024] In some preferred embodiments of the present invention, the particle stabilizer is 10 mg / mL Tween 20 and 30 mg / mL polyethylene glycol 4000, 5 mg / mL Tween 20 and 15 mg / mL polyethylene glycol 4000, 5 mg / mL Tween 20 and 30 mg / mL polyethylene glycol 4000, or 10 mg / mL poloxamer 188, 10 mg / mL Tween 20 and 30 mg / mL polyethylene glycol 4000.
[0025] The buffer salt is preferably one or more of disodium hydrogen phosphate, disodium hydrogen phosphate dodecahydrate, dipotassium hydrogen phosphate, dipotassium hydrogen phosphate trihydrate, potassium dihydrogen phosphate and sodium dihydrogen phosphate, such as disodium hydrogen phosphate dodecahydrate and potassium dihydrogen phosphate.
[0026] The content of the buffer salt is preferably 3-5 mg / mL, such as 3.87 mg / mL.
[0027] When the buffer salt is disodium hydrogen phosphate dodecahydrate and potassium dihydrogen phosphate, the content of the disodium hydrogen phosphate dodecahydrate is preferably 3-4 mg / mL, such as 3.63 mg / mL; the content of the potassium dihydrogen phosphate is preferably 0.1-1 mg / mL, such as 0.24 mg / mL.
[0028] The isotonicity adjusting agent is preferably sodium chloride and potassium chloride.
[0029] The content of the isotonicity regulator is preferably 7-10 mg / mL, such as 8.2 mg / mL.
[0030] When the isotonicity adjusting agents are sodium chloride and potassium chloride, the content of potassium chloride is preferably 0.1-0.3 mg / mL, such as 0.2 mg / mL; the content of sodium chloride is preferably 7.0-9.0 mg / mL, such as 8.0 mg / mL.
[0031] The water is preferably water for injection.
[0032] The pH value of the epiriprazole laurate suspension is preferably 5.0-8.0, more preferably 7.1-7.3, such as 7.2.
[0033] The epiriprazole laurate suspension has better patient tolerance within the above pH range. In certain specific embodiments of the present invention, the pH value of the epiriprazole laurate suspension is adjusted to within the above range by adding an appropriate amount of buffer salt.
[0034] The epiriprazole laurate suspension provided by the present invention is preferably composed of the following components: 10-1000 mg / mL epiriprazole laurate particles, 10-60 mg / mL particle stabilizer, 3-5 mg / mL buffer salt, 7-10 mg / mL isotonicity regulator and water, wherein mg / mL is the ratio of the mass of each component in the epiriprazole laurate suspension to the volume of water in the epiriprazole laurate suspension.
[0035] The epiriprazole laurate suspension provided by the present invention is preferably composed of the following components: 75-223.45 mg / mL of epiriprazole laurate particles, 5-10 mg / mL of Tween 20, 15-30 mg / mL of polyethylene glycol 4000, 0-10 mg / mL of poloxamer 188, 3.63 mg / mL of disodium hydrogen phosphate dodecahydrate, 0.24 mg / mL of potassium dihydrogen phosphate, 0.2 mg / mL of potassium chloride, 8.0 mg / mL of sodium chloride and water, wherein mg / mL is the ratio of the mass of each component in the epiriprazole laurate suspension to the volume of water in the epiriprazole laurate suspension.
[0036] In a preferred embodiment of the present invention, the epiriprazole laurate suspension is composed of the following components: 223.45 mg / mL epiriprazole laurate particles, 10 mg / mL Tween 20, 30 mg / mL polyethylene glycol 4000, 3.63 mg / mL disodium hydrogen phosphate dodecahydrate, 0.24 mg / mL potassium dihydrogen phosphate, 0.2 mg / mL potassium chloride, 8.0 mg / mL sodium chloride and water, wherein mg / mL is the ratio of the mass of each component in the epiriprazole laurate suspension to the volume of water in the epiriprazole laurate suspension;
[0037] Wherein, the D of the epiriprazole laurate granules is 10 1.5μm, D 50 4.0μm, D 90 The particle size distribution span is 2.7.
[0038] In a preferred embodiment of the present invention, the epiriprazole laurate suspension is composed of the following components: 223.45 mg / mL epiriprazole laurate particles, 10 mg / mL Tween 20, 30 mg / mL polyethylene glycol 4000, 3.63 mg / mL disodium hydrogen phosphate dodecahydrate, 0.24 mg / mL potassium dihydrogen phosphate, 0.2 mg / mL potassium chloride, 8.0 mg / mL sodium chloride and water, wherein mg / mL is the ratio of the mass of each component in the epiriprazole laurate suspension to the volume of water in the epiriprazole laurate suspension;
[0039] Wherein, the D of the epiriprazole laurate granules is 10 0.93μm, D 50 2.21 μm, D 90 The particle size distribution span is 2.3.
[0040] In a preferred embodiment of the present invention, the epiriprazole laurate suspension is composed of the following components: 223.45 mg / mL epiriprazole laurate particles, 10 mg / mL Tween 20, 30 mg / mL polyethylene glycol 4000, 10 mg / mL poloxamer 188, 3.63 mg / mL disodium hydrogen phosphate dodecahydrate, 0.24 mg / mL potassium dihydrogen phosphate, 0.2 mg / mL potassium chloride, 8.0 mg / mL sodium chloride and water, wherein mg / mL is the ratio of the mass of each component in the epiriprazole laurate suspension to the volume of water in the epiriprazole laurate suspension;
[0041] Wherein, the D of the epiriprazole laurate granules is 10 1.4μm, D 50 3.6μm, D 90 The particle size distribution span is 2.5.
[0042] In a preferred embodiment of the present invention, the epiriprazole laurate suspension is composed of the following components: 75 mg / mL epiriprazole laurate particles, 5 mg / mL Tween 20, 15 mg / mL polyethylene glycol 4000, 3.63 mg / mL disodium hydrogen phosphate dodecahydrate, 0.24 mg / mL potassium dihydrogen phosphate, 0.2 mg / mL potassium chloride, 8.0 mg / mL sodium chloride and water, wherein mg / mL is the ratio of the mass of each component in the epiriprazole laurate suspension to the volume of water in the epiriprazole laurate suspension;
[0043] Wherein, the D of the epiriprazole laurate granules is 10 2.0μm, D 50 4.1μm, D 90 The particle size distribution span is 1.2.
[0044] In a preferred embodiment of the present invention, the epiriprazole laurate suspension is composed of the following components: 75 mg / mL epiriprazole laurate particles, 5 mg / mL Tween 20, 15 mg / mL polyethylene glycol 4000, 3.63 mg / mL disodium hydrogen phosphate dodecahydrate, 0.24 mg / mL potassium dihydrogen phosphate, 0.2 mg / mL potassium chloride, 8.0 mg / mL sodium chloride and water, wherein mg / mL is the ratio of the mass of each component in the epiriprazole laurate suspension to the volume of water in the epiriprazole laurate suspension;
[0045] Wherein, the D of the epiriprazole laurate granules is 10 3.3μm, D 50 6.0μm, D 90 The particle size distribution span is 1.2.
[0046] In a preferred embodiment of the present invention, the epiriprazole laurate suspension is composed of the following components: 200 mg / mL epiriprazole laurate particles, 5 mg / mL Tween 20, 30 mg / mL polyethylene glycol 4000, 10 mg / mL poloxamer 188, 3.63 mg / mL disodium hydrogen phosphate dodecahydrate, 0.24 mg / mL potassium dihydrogen phosphate, 0.2 mg / mL potassium chloride, 8.0 mg / mL sodium chloride and water, wherein mg / mL is the ratio of the mass of each component in the epiriprazole laurate suspension to the volume of water in the epiriprazole laurate suspension;
[0047] Wherein, the D of the epiriprazole laurate granules is 10 1.0μm, D 50 1.8μm, D 90 The particle size distribution span is 1.2.
[0048] In a preferred embodiment of the present invention, the epiriprazole laurate suspension is composed of the following components: 200 mg / mL epiriprazole laurate particles, 5 mg / mL Tween 20, 30 mg / mL polyethylene glycol 4000, 10 mg / mL poloxamer 188, 3.63 mg / mL disodium hydrogen phosphate dodecahydrate, 0.24 mg / mL potassium dihydrogen phosphate, 0.2 mg / mL potassium chloride, 8.0 mg / mL sodium chloride and water, wherein mg / mL is the ratio of the mass of each component in the epiriprazole laurate suspension to the volume of water in the epiriprazole laurate suspension;
[0049] Wherein, the D of the epiriprazole laurate granules is 10 1.3μm, D 50 2.5μm, D 90The particle size distribution span is 1.3.
[0050] The epiriprazole laurate suspension is preferably an injection.
[0051] In the present invention, the epiriprazole laurate suspension is ready-to-use and only needs to be fully mixed before use without adding other media for re-suspending.
[0052] The present invention provides a method for preparing an epiriprazole laurate suspension, which comprises the following steps: mixing epiriprazole laurate primary particles with a mixture A, and obtaining an intermediate suspension by ultrasonic stirring and / or shearing, and preparing the epiriprazole laurate suspension by a microjet high-pressure homogenization method using the intermediate suspension;
[0053] Wherein, mixture A is composed of particle stabilizer, buffer salt, isotonicity regulator and water.
[0054] In the preparation method, the primary particles of epiriprazole laurate are prepared by at least one of recrystallization, grinding and sieving, preferably by recrystallization. The solvent for the recrystallization is preferably acetone.
[0055] The primary particles of epiriprazole laurate are in the form of an amorphous substance or a crystalline form of epiriprazole laurate, preferably epiriprazole laurate crystalline form A. The powder diffraction (XRPD) pattern of the epiriprazole laurate crystalline form A has characteristic peaks at diffraction angles (2θ) of 3.7±0.2°, 6.4±0.2°, 11.2±0.2°, 12.7±0.2°, 14.8±0.2°, 15.0±0.2°, 18.5±0.2°, 19.0±0.2°, 19.7±0.2°, 20.2±0.2°, 21.7±0.2°, and 23.4±0.2°.
[0056] The average particle diameter of the epiriprazole laurate primary particles is preferably 0.1 to 50 μm, for example 30.4 μm.
[0057] In the preparation method, the dosage of the primary particles of epiriprazole laurate is preferably 10-1000 mg / mL, more preferably 50-250 mg / mL, such as 75 mg / mL, 200 mg / mL or 223.45 mg / mL.
[0058] In the preparation method, mg / mL is the ratio of the mass of the primary particles of epiriprazole laurate or the mass of each component in the mixture A to the volume of water in the mixture A.
[0059] In the preparation method, the particle stabilizer is preferably one or more of poloxamer, polyvinyl pyrrolidone, hydroxypropyl methylcellulose, Tween and polyethylene glycol. The polyethylene glycol is preferably polyethylene glycol 4000. The poloxamer is preferably poloxamer 188 or poloxamer 407. The hydroxypropyl methylcellulose is preferably hydroxypropyl methylcellulose E3 or hydroxypropyl methylcellulose E5. The Tween is preferably Tween 80 or Tween 20. The particle stabilizer is more preferably Tween 20 and polyethylene glycol 4000, or, poloxamer 188, Tween 20 and polyethylene glycol 4000.
[0060] In the preparation method, the dosage of the particle stabilizer is preferably 10-60 mg / mL, such as 20 mg / mL, 40 mg / mL, 45 mg / mL or 50 mg / mL.
[0061] In the preparation method, when the particle stabilizers are Tween 20 and polyethylene glycol 4000, the dosage of Tween 20 is preferably 5-10 mg / mL; the dosage of polyethylene glycol 4000 is preferably 15-30 mg / mL.
[0062] In the preparation method, when the particle stabilizers are poloxamer 188, Tween 20 and polyethylene glycol 4000, the dosage of Tween 20 is preferably 5-10 mg / mL; the dosage of polyethylene glycol 4000 is preferably 15-30 mg / mL; and the dosage of poloxamer 188 is preferably 10 mg / mL.
[0063] In the preparation method, the particle stabilizer is preferably 10 mg / mL Tween 20 and 30 mg / mL polyethylene glycol 4000, 5 mg / mL Tween 20 and 15 mg / mL polyethylene glycol 4000, 5 mg / mL Tween 20 and 30 mg / mL polyethylene glycol 4000, or 10 mg / mL poloxamer 188, 10 mg / mL Tween 20 and 30 mg / mL polyethylene glycol 4000.
[0064] In the preparation method, the buffer salt is preferably one or more of disodium hydrogen phosphate, disodium hydrogen phosphate dodecahydrate, dipotassium hydrogen phosphate, dipotassium hydrogen phosphate trihydrate, potassium dihydrogen phosphate and sodium dihydrogen phosphate, such as disodium hydrogen phosphate dodecahydrate and potassium dihydrogen phosphate.
[0065] In the preparation method, the amount of the buffer salt is preferably 3-5 mg / mL, such as 3.87 mg / mL.
[0066] In the preparation method, when the buffer salt is disodium hydrogen phosphate dodecahydrate and potassium dihydrogen phosphate, the dosage of the disodium hydrogen phosphate dodecahydrate is preferably 3-4 mg / mL, such as 3.63 mg / mL; the dosage of the potassium dihydrogen phosphate is preferably 0.1-1 mg / mL, such as 0.24 mg / mL.
[0067] In the preparation method, the isotonicity regulator is preferably sodium chloride and potassium chloride.
[0068] The dosage of the isotonicity adjusting agent is preferably 7-10 mg / mL, such as 8.2 mg / mL.
[0069] In the preparation method, when the isotonicity adjusting agents are sodium chloride and potassium chloride, the amount of potassium chloride is preferably 0.1-0.3 mg / mL, such as 0.2 mg / mL; the amount of sodium chloride is preferably 7.0-9.0 mg / mL, such as 8.0 mg / mL.
[0070] In the preparation method, the water is preferably water for injection.
[0071] In the preparation method, the mixture A is preferably composed of the following components: 10-60 mg / mL of a particle stabilizer, 3-5 mg / mL of a buffer salt, 7-10 mg / mL of an isotonic regulator and water, wherein mg / mL is the ratio of the mass of each component in the mixture A to the volume of water in the mixture A.
[0072] In the preparation method, the mixture A is preferably composed of the following components: 5-10 mg / mL Tween 20, 15-30 mg / mL polyethylene glycol 4000, 0-10 mg / mL poloxamer 188, 3.63 mg / mL disodium hydrogen phosphate dodecahydrate, 0.24 mg / mL potassium dihydrogen phosphate, 0.2 mg / mL potassium chloride, 8.0 mg / mL sodium chloride and water, wherein mg / mL is the ratio of the mass of each component in the mixture A to the volume of water in the mixture A.
[0073] In the preparation method, the mixing is preferably carried out under ultrasound.
[0074] In the preparation method, the shearing speed is preferably 5000-15000 rpm, such as 10000 rpm. The shearing time is preferably 3-10 minutes, such as 5 minutes.
[0075] In the microfluidization high pressure homogenization method, the homogenization pressure is preferably 2000-25000 psi, such as 5000 psi, 8000 psi, 10000 psi, 15000 psi, 20000 psi or 24000 psi.
[0076] In the microfluidization high pressure homogenization method, the homogenization times are preferably 5-25 times, for example 8 times, 10 times, 12 times, 15 times or 20 times.
[0077] In the micro-jet high-pressure homogenization method, the aperture of the nozzle is preferably 10-30 mm, more preferably 13-25 mm.
[0078] The invention provides an epiriprazole laurate suspension, which is prepared by the above preparation method.
[0079] The present invention also provides the use of the above-mentioned epiriprazole laurate suspension in the preparation of a drug for treating or preventing a disease, wherein the disease is schizophrenia, bipolar disorder or relapse of depression.
[0080] In certain embodiments of the present invention, the intramuscular administration of the suspension of lauric acid laurate can provide an exposure of lauric acid laurate higher than the effective therapeutic concentration for up to 2 to 4 weeks in animals.
[0081] On the basis of being in accordance with the common sense in the art, the above-mentioned preferred conditions can be arbitrarily combined to obtain the preferred embodiments of the present invention.
[0082] The reagents and raw materials used in the present invention are commercially available.
[0083] The positive and progressive effects of the present invention are:
[0084] 1. The suspension of ipriprazole laurate in the present invention is the first long-acting injection form of ipriprazole laurate.
[0085] 2. The suspension of lauric acid pyrimethamine in the present invention has better stability than suspensions of pyrimethamine or pyrimethamine dihydrate, and is more suitable for development into high-quality medicines.
[0086] 3. The preparation method of the lauric acid suspension of irinotecan is simple to operate, has a short production cycle, does not require time-consuming and expensive processes such as freeze-drying, and significantly reduces the production cost of the drug.
[0087] 4. The lauric acid ester suspension of irinotecan in the present invention can provide irinotecan exposure higher than the effective therapeutic concentration for up to 2 to 4 weeks, has better in vivo release behavior than irinotecan or irinotecan dihydrate suspension, can significantly improve the adverse reactions caused by sudden drug release, and is more easily absorbed by the body to reduce the amount of drug used, and therefore has better clinical application value.
[0088] Definition of terms
[0089] The term "D 10 ”, “D 50 ”, “D90 " refers to the standard percentile reading of particle size analysis measured by laser diffraction scattering method. For example, using Malvern Mastersizer 3000 intelligent laser particle size analyzer, using a wet dispersion device and water as the medium, "D 10 " represents that 10% of the sample particle size values are lower than this value, "D 50 " represents that 50% of the sample particle size values are lower than this value, "D 90 " represents that 90% of the sample particle size values are lower than this value. "Average particle diameter" is the volume-weighted average of the particle sizes measured under the same test conditions as above.
[0090] The term "span of particle size distribution" (SPAN) is a measure of the width of the distribution and is expressed by the formula: SPAN = (D 90 -D 10 )÷D50, calculated. BRIEF DESCRIPTION OF THE DRAWINGS
[0091] Figure 1 This is a powder diffraction comparison diagram of the raw material of epirinotecan laurate crystalline form A in the accelerated stability study and after being prepared into epirinotecan laurate suspension BPZL-D2.
[0092] Figure 2 The solubility comparison of ipriprazole laurate crystalline form A and ipriprazole in Example 4 is shown in FIG.
[0093] Figure 3 This is the change process of particle size as the number of homogenization times increases under the condition of 8000psi in the microfluidic high-pressure homogenization method in Example 5.
[0094] Figure 4 This is the change process of particle size as the number of homogenization times increases under the condition of 24000psi in the microfluidic high-pressure homogenization method in Example 6.
[0095] Figure 5 The pharmacokinetic curves of the epiriprazole laurate suspensions BPZL-X3 and BPZL-D3 with different particle sizes in Example 10 in beagle dogs.
[0096] Figure 6 The pharmacokinetic curves of the same dose of epiriprazole dihydrate suspension BPZ-D2 and epiriprazole laurate suspension BPZL-D2 in rats in Example 11 are shown in FIG. DETAILED DESCRIPTION
[0097] The present invention is further described below by way of examples, but the present invention is not limited to the scope of the examples. The experimental methods in the following examples without specifying specific conditions are carried out according to conventional methods and conditions, or selected according to the product specifications.
[0098] The raw material epiriprazole and other raw materials, reagents and solvents used in the following examples are all commercially available.
[0099] Example 1: Preparation of epriprazole laurate
[0100]
[0101] Take 10.0g of epipiprazole and place it in a 500mL three-necked flask, dissolve it in 200mL tetrahydrofuran (THF) until it is clear, and then add 2.8g NaH. After stirring at room temperature for 15 minutes, add 11.4g of chloromethyl laurate dropwise with an addition funnel, and add 1.0g KI. Heat the reaction solution to 40°C, stir the reaction for 2h and then cool to room temperature, then pour the reaction solution into a mixed solution of ethyl acetate and ice water to quench. Finally, transfer the mixed solution to a separating funnel for separation, wash the upper layer twice with a saturated sodium chloride solution, and then remove the remaining moisture with anhydrous sodium sulfate. After being spin-dried, obtain about 15.0g of epipiprazole laurate crude product. 1 HNMR (400MHz, CDCl 3 ): δ7.61(d,J=9.5Hz,1H),7.54(d,J=8.0Hz,1H),7.40(dt,J=13.5,7.1Hz,3H),7.26(t,J=7.8Hz,1 H),6.88(d,J=7.6Hz,2H),6.83(dd,J=8.6,2.1Hz,1H),6.51(d,J=9.5Hz,1H),6.33(s,2H),4.08(t, J=6.2Hz,2H),3.19(s,4H),2.73(s,4H),2.57-2.49(m,2H),2.35(t,J=7.5Hz,2H),1.94-1.84(m,2H ), 1.77 (dt, J = 14.7, 7.4Hz, 2H), 1.66-1.56 (m, 2H), 1.25 (d, J = 27.1Hz, 18H), 0.87 (t, J = 6.9Hz, 3H).
[0102] Example 2: Preparation of Crystalline Form A of Epiprazole Laurate
[0103] Take 10g of the crude product of lauric acid ester of epiriprazole prepared in Example 1, add 100mL of acetone to form a solution. Stir for 2h at a low temperature of -20°C and a stirring speed of 100 rpm to gradually precipitate a white solid. After filtering the white solid, wash it twice with 5mL of acetone, place it in a vacuum drying oven at -0.08Mpa and 40°C and dry it for 2h. Repeat the above operation 2 to 3 times until the content of lauric acid ester of epiriprazole is >99.0%. The content was determined to be 99.62% by high performance liquid chromatography. The specific conditions of HPLC are: the chromatographic column is Welch LP-C18 (250*4.6mm, 5μm), column temperature 40℃; mobile phase A is pure acetonitrile, mobile phase B is 0.15% triethylamine aqueous solution (pH 3.50), mobile phase ratio A:B is 90:10; injection volume is 10μL; flow rate is 1.2mL / min; detection wavelength is 220nm. The average particle diameter measured by laser diffraction scattering method is 30.4μm. The spectrum of the prepared lauric acid ester crystal A determined by X-ray powder diffraction analysis is as follows Figure 1 As shown in (BPZL-raw-initial), the diffraction angle 2θ has characteristic peaks at 3.7±0.2°, 6.4±0.2°, 9.1±0.2°, 11.2±0.2°, 12.7±0.2°, 14.8±0.2°, 15.0±0.2°, 16.3±0.2°, 18.5±0.2°, 19.0±0.2°, 19.7±0.2°, 20.2±0.2°, 21.2±0.2°, 21.7±0.2°, 22.3±0.2°, 23.4±0.2°, 25.2±0.2°, and 28.6±0.2°.
[0104] Example 3: Stability test of epriprazole laurate crystal form A under high temperature, high humidity and light conditions
[0105] The crystalline form A of lauric acid ester of epiprazole prepared in Example 2 was subjected to a stability test. The samples were placed under high temperature of 60°C, high humidity of 92.5%, and light of 4500 lx for 10 days. The content was determined by high performance liquid chromatography, and no degradation impurities were detected. The spectrum of the sample determined by X-ray powder diffraction analysis is as follows: Figure 1 As shown, the crystal form of epriprazole laurate form A did not change after being placed under high temperature, high humidity and light conditions for 10 days.
[0106] Example 4: Solubility comparison of epriprazole laurate and epriprazole
[0107] The 1-octanol and water solubility of BPZL prepared in Example 2 was compared with that of BPZ at room temperature. The excess drug (three parallel experiments) was mixed with the solvent by appropriate ultrasonic stirring, placed on a Thermo Scientific Tube Revolver, and rotated at 15 rpm for 48 hours. The sample was centrifuged at 12000 rpm for 10 minutes to separate the soluble drug from the insoluble particles, and diluted with MeOH to an appropriate concentration for analysis. The solubility was calculated as Figure 2 As shown, the 1-octanol solubility of lauric acid ester form A of epriprazole is about 10 times that of epriprazole, while the water solubility is reduced by 10 times.
[0108] Example 5: Preparation of epiriprazole dihydrate suspension BPZ-D1 and epiriprazole laurate suspension BPZL-D1
[0109] The commercially available epiriprazole dihydrate and epiriprazole laurate crystal form A prepared according to Example 2 were taken in the prescribed amounts shown in Table 1 below, and added to the auxiliary material aqueous solution of the same concentration by ultrasonic stirring (the preparation process of the auxiliary material aqueous solution is as follows: various auxiliary materials in the prescribed amount are dissolved in a certain amount of water, and the auxiliary material aqueous solution is obtained by simple stirring or ultrasonication. The preparation methods of the auxiliary material aqueous solutions in the following embodiments are the same); respectively, they were subjected to high-speed shearing at 10,000 rpm for 5 minutes to obtain an intermediate suspension; respectively, they were subjected to microjet high-pressure homogenization method, with a nozzle aperture of 25 mm, and the homogenization pressure was 8000 psi. When the cycle was repeated 5 times, 8 times, 10 times, and 12 times, the particle size reduction process was as follows: Figure 3 After 12 cycles, BPZ-D1 and BPZL-D1 suspensions were obtained, and their particle size distribution data are shown in Table 1. The pH values of the BPZ-D1 and BPZL-D1 suspensions were both 7.2 (determined according to the pH determination method in 0631 of Part IV of the 2020 edition of the Chinese Pharmacopoeia).
[0110] Table 1
[0111]
[0112] like Figure 3 It is shown that under the process conditions, a suspension with an average particle diameter of about 5 μm can be prepared with high preparation efficiency, and the particle size is basically uniform after 5 cycles; under the same process conditions, the particle size of BPZL is smaller than that of BPZ, which shows that compared with BPZ, the crushing efficiency of BPZL is higher.
[0113] Example 6: Preparation of epiriprazole dihydrate suspension BPZ-X1 and epiriprazole laurate suspension BPZL-X1
[0114] The commercially available epiriprazole dihydrate and epiriprazole laurate crystal form A prepared according to Example 2 were taken in the prescribed amounts shown in Table 2, and added to the auxiliary material aqueous solution of the same concentration by ultrasonic stirring; the intermediate suspension was obtained by high-speed shearing at 10,000 rpm for 5 minutes; the intermediate suspension was obtained by microfluidization high-pressure homogenization with a nozzle aperture of 25 mm and a homogenization pressure of 24,000 psi for 5, 8, 10, 12, 15, and 20 cycles, respectively. The particle size reduction process was as follows: Figure 4 After 20 cycles, BPZ-X1 and BPZL-X1 suspensions were obtained, and their particle size distribution data are shown in Table 2. The pH values of the BPZ-X1 and BPZL-X1 suspensions were both 7.2 (determined according to the pH determination method in 0631 of Part IV of the 2020 edition of the Chinese Pharmacopoeia).
[0115] Table 2
[0116]
[0117]
[0118] like Figure 4 It is shown that under this process condition, a suspension with an average particle diameter of about 2μm can be prepared by increasing the mean pressure, and the particle size is basically uniform after 5 cycles. However, after the prepared suspension was placed for 4 weeks, BPZ-X1 had serious agglomeration and a significant change in particle size, while the particle size of BPZL-X1 increased slightly. Therefore, it is suggested that a better stabilizer combination needs to be further explored in the contact of this prescription so that it can be applied to suspensions of all particle sizes.
[0119] Example 7: Preparation of epiriprazole dihydrate suspension BPZ-D2 and epiriprazole laurate suspension BPZL-D2
[0120] Take the commercially available epiriprazole dihydrate and epiriprazole laurate crystal form A of the prescription amount shown in Table 3 below, respectively, and add them to the same concentration of auxiliary material aqueous solution by ultrasonic stirring; respectively, under high-speed shearing conditions of 10,000 rpm for 5 minutes to obtain an intermediate suspension; respectively, by micro-jet high-pressure homogenization method, the nozzle aperture is 25 mm, and the homogenization pressure is 24,000 psi. 20 cycles to obtain the final suspension. The prepared suspensions BPZ-D2 and BPZL-D2 were stored at room temperature for 2 years, and the parameters such as particle size distribution and span were sampled and measured as shown in Table 3 below. The pH values of the BPZ-D2 and BPZL-D2 suspensions are both 7.2 (determined according to the pH determination method in 0631 of the General Rules of Part IV of the 2020 Chinese Pharmacopoeia).
[0121] BPZL-D2 has good particle size stability and is easily dispersed by light shaking; only a small part of BPZ-D2 can be redispersed after long-term shaking, and most samples have serious agglomeration.
[0122] Table 3
[0123]
[0124] Example 8: Preparation of epiriprazole laurate suspensions BPZL-X3 and BPZL-D3
[0125] Take the crystalline form A of lauric acid laurate prepared according to Example 2 in the amount shown in Table 4, and add them to the excipient aqueous solution of the same concentration by ultrasonic stirring; respectively, under high-speed shearing conditions of 10,000 rpm for 5 minutes to obtain an intermediate suspension; by microjet high-pressure homogenization method, the nozzle aperture is 25 mm, and the homogenization pressure is 5,000 psi and 15,000 psi, respectively, and the suspensions BPZL-D3 and BPZL-X3 are prepared. The parameters such as particle size distribution and span are measured as shown in Table 4 below. The pH values of the BPZL-D3 and BPZL-X3 suspensions are both 7.2 (determined according to the pH determination method in 0631 of the General Rules of Part IV of the 2020 Edition of the Chinese Pharmacopoeia). These two batches of preparations were prepared for in vivo pharmacokinetic experiments in beagle dogs to explore the differences between different particle sizes in practical applications.
[0126] Table 4
[0127]
[0128]
[0129] Example 9: Preparation of epiriprazole laurate suspensions BPZL-X4 and BPZL-D4
[0130] Take the crystalline form A of lauric acid laurate prepared according to Example 2 in the amount shown in Table 5, respectively, and add them to the excipient aqueous solution of the same concentration by ultrasonic stirring; respectively, under high-speed shearing conditions of 10,000 rpm for 5 minutes to obtain an intermediate suspension; by microjet high-pressure homogenization method, the nozzle aperture is 13 mm, and the homogenization pressure is 10,000 psi and 20,000 psi, respectively, and the suspensions BPZL-D4 and BPZL-X4 are prepared. The parameters such as particle size distribution and span are measured at room temperature for six months as shown in Table 5 below, and the particle size stability and redispersibility are good. The pH values of the BPZL-X4 and BPZL-D4 suspensions are both 7.2 (determined according to the pH value determination method in 0631 of the General Rules of Part IV of the 2020 Chinese Pharmacopoeia).
[0131] Table 5
[0132]
[0133]
[0134] Example 10: Pharmacokinetics of epiridol laurate suspension in beagle dogs
[0135] Six male beagle dogs (weighing 10.0-12.3 kg) were randomly divided into two groups and injected with 2 mg / kg of the epiridol laurate suspension BPZL-X3 and BPZL-D3 prepared according to Example 8 into the left gluteus maximus muscle. At predetermined time intervals (1, 2, 4, 6, 8, 12 hours and 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 13, 15, 18, 22 days), 1.0 mL of blood samples were collected from the left front leg vein into heparinized tubes and centrifuged at 12000 rpm for 5 min. The plasma supernatant was collected and the exposure of epiridol in plasma was determined by HPLC-MS / MS method. The pharmacokinetic curve was calculated as follows: Figure 5 The statistical moment parameters are shown in Table 6 below. The data of the oral group in the table are the values reported in the literature of Rexulti (J Chromatogr Sci, 2018, 56(8):702-708.). It can be seen that the Rexulti laurate suspensions BPZL-X3 and BPZL-D3 have significantly prolonged half-lives compared with commercially available oral tablets, and can achieve sustained release of different periods by controlling the size of the particles.
[0136] Table 6
[0137]
[0138] Example 11: Comparison of the pharmacokinetics of epiriprazole dihydrate suspension and epiriprazole laurate suspension in rats
[0139] Ten male SD rats (weighing 250±20g) were randomly divided into two groups and injected with the same 60mg / kg dose of BPZ-D2, a suspension of irinotecan dihydrate, and BPZL-D2, a suspension of irinotecan laurate, prepared according to Example 7, into the left hind limb. At predetermined time intervals (1, 4, 8 hours and 1, 2, 3, 5, 6, 7, 8, 11, 14, 17, 18, 21, 25, 28, 35, 42, 54, 63 days), 0.3mL of blood samples were collected from the rat eye sockets into heparinized tubes and centrifuged at 12000rpm for 5min. The plasma supernatant was collected and the exposure of irinotecan in the plasma was determined by HPLC-MS / MS. The pharmacokinetic curve was calculated as follows: Figure 6 The statistical moment parameters are shown in Table 7. 50) The existing literature reports (J Pharmacol Exp Ther, 2014, 350: 589-604.) is 49 ng / mL. Therefore, it can be seen from the data that compared with the suspension of irinotecan dihydrate, the in vivo absorption of irinotecan laurate suspension is better, and it does not require freeze-drying to avoid sudden release of the drug after injection.
[0140] Table 7
[0141]
[0142] Therefore, compared with the epiriprazole dihydrate suspension, the epiriprazole laurate suspension has better clinical application value.
Claims
1. An epiriprazole laurate suspension, characterized in that: It includes epriprazole laurate particles as shown in formula I and water; 2. The epiriprazole laurate suspension according to claim 1, characterized in that The epiriprazole laurate suspension further comprises a particle stabilizer, a buffer salt and an isotonicity regulator.
3. The epiriprazole laurate suspension according to claim 1, characterized in that The epiriprazole laurate suspension consists of epiriprazole laurate particles, particle stabilizer, buffer salt, isotonicity regulator and water.
4. The epiriprazole laurate suspension according to claim 3, characterized in that The epiriprazole laurate suspension satisfies one or more of the following conditions: (1) The lauric acid ester particles are in the amorphous or crystalline form of lauric acid ester, preferably particles of lauric acid ester crystal form A; (2) the content of the epiriprazole laurate particles is 10-1000 mg / mL, preferably 50-250 mg / mL, for example 75 mg / mL, 200 mg / mL or 223.45 mg / mL; (3) The epiriprazole laurate granules D 10 0.5-5.0 μm, preferably 0.8-4.0 μm, for example 0.93 μm, 1.0 μm, 1.3 μm, 1.4 μm, 1.5 μm, 2.0 μm or 3.3 μm; (4) The epipiprazole laurate granules D 50 1.0-10.0 μm, preferably 1.5-8.0 μm, for example 1.8 μm, 2.21 μm, 2.5 μm, 3.6 μm, 4.0 μm, 4.1 μm or 6.0 μm; (5) The epipiprazole laurate granules D 90 2.0-30.0 μm, preferably 3.0-20.0 μm, for example 3.1 μm, 4.7 μm, 6.0 μm, 7.0 μm, 10.4 μm, 10.5 μm or 12.2 μm; (6) The particle size distribution span of the epiriprazole laurate particles is 0.5-3.0, preferably 1.0-3.0, for example 1.2, 1.3, 2.3, 2.5 or 2.7; (7) The particle stabilizer is one or more of polyethylene glycol, polyvinyl pyrrolidone, poloxamer, hydroxypropyl methylcellulose and Tween; the polyethylene glycol is preferably polyethylene glycol 4000; the poloxamer is preferably poloxamer 188 or poloxamer 407; the hydroxypropyl methylcellulose is preferably hydroxypropyl methylcellulose E3 or hydroxypropyl methylcellulose E5; the Tween is preferably Tween 80 or Tween 20; the particle stabilizer is more preferably Tween 20 and polyethylene glycol 4000, or, poloxamer 188, Tween 20 and polyethylene glycol 4000; (8) The content of the particle stabilizer is 10-60 mg / mL, for example, 20 mg / mL, 40 mg / mL, 45 mg / mL or 50 mg / mL; (9) The buffer salt is one or more of disodium hydrogen phosphate, disodium hydrogen phosphate dodecahydrate, dipotassium hydrogen phosphate, dipotassium hydrogen phosphate trihydrate, potassium dihydrogen phosphate and sodium dihydrogen phosphate, such as disodium hydrogen phosphate dodecahydrate and potassium dihydrogen phosphate; (10) The content of the buffer salt is 3-5 mg / mL, for example 3.87 mg / mL; (11) The isotonicity adjusting agent is sodium chloride and potassium chloride; (12) The content of the isotonicity adjusting agent is 7-10 mg / mL, for example 8.2 mg / mL; (13) The water is water for injection; (14) The pH value of the epiriprazole laurate suspension is 5.0-8.
0.
5. The epiriprazole laurate suspension according to claim 3, characterized in that: The epiriprazole laurate suspension satisfies one or more of the following conditions: (1) When the particle stabilizers are Tween 20 and polyethylene glycol 4000, the content of Tween 20 is 5-10 mg / mL; the content of polyethylene glycol 4000 is 15-30 mg / mL; (2) When the particle stabilizer is poloxamer 188, Tween 20 and polyethylene glycol 4000, the content of Tween 20 is 5-10 mg / mL; the content of polyethylene glycol 4000 is 15-30 mg / mL; the content of poloxamer 188 is 10 mg / mL; (3) When the buffer salt is disodium hydrogen phosphate dodecahydrate and potassium dihydrogen phosphate, the content of disodium hydrogen phosphate dodecahydrate is 3-4 mg / mL, for example, 3.63 mg / mL; the content of potassium dihydrogen phosphate is 0.1-1 mg / mL, for example, 0.24 mg / mL; (4) When the isotonicity adjusting agents are sodium chloride and potassium chloride, the content of potassium chloride is 0.1-0.3 mg / mL, for example, 0.2 mg / mL; the content of sodium chloride is 7.0-9.0 mg / mL, for example, 8.0 mg / mL; (5) The epiriprazole laurate suspension is an injection; (6) The pH value of the epiriprazole laurate suspension is 7.1-7.3, for example 7.
2.
6. The epiriprazole laurate suspension according to claim 3, characterized in that The epiriprazole laurate suspension is composed of the following components: 10-1000 mg / mL epiriprazole laurate particles, 10-60 mg / mL particle stabilizer, 3-5 mg / mL buffer salt, 7-10 mg / mL isotonicity regulator and water, wherein mg / mL is the ratio of the mass of each component in the epiriprazole laurate suspension to the volume of water in the epiriprazole laurate suspension; Preferably, the epiriprazole laurate suspension is composed of the following components: 75-223.45 mg / mL of epiriprazole laurate particles, 5-10 mg / mL of Tween 20, 15-30 mg / mL of polyethylene glycol 4000, 0-10 mg / mL of poloxamer 188, 3.63 mg / mL of disodium hydrogen phosphate dodecahydrate, 0.24 mg / mL of potassium dihydrogen phosphate, 0.2 mg / mL of potassium chloride, 8.0 mg / mL of sodium chloride and water, wherein mg / mL is the ratio of the mass of each component in the epiriprazole laurate suspension to the volume of water in the epiriprazole laurate suspension.
7. The epiriprazole laurate suspension according to claim 3, characterized in that The epiriprazole laurate suspension satisfies one of the following conditions: (1) The epiriprazole laurate suspension is composed of the following components: 223.45 mg / mL of epiriprazole laurate particles, 10 mg / mL of Tween 20, 30 mg / mL of polyethylene glycol 4000, 3.63 mg / mL of disodium hydrogen phosphate dodecahydrate, 0.24 mg / mL of potassium dihydrogen phosphate, 0.2 mg / mL of potassium chloride, 8.0 mg / mL of sodium chloride and water, wherein mg / mL is the ratio of the mass of each component in the epiriprazole laurate suspension to the volume of water in the epiriprazole laurate suspension; Wherein, the D of the epiriprazole laurate granules is 10 1.5μm, D 50 4.0μm, D 90 is 12.2 μm, and the particle size distribution span is 2.7; (2) The epiriprazole laurate suspension is composed of the following components: 223.45 mg / mL epiriprazole laurate particles, 10 mg / mL Tween 20, 30 mg / mL polyethylene glycol 4000, 3.63 mg / mL disodium hydrogen phosphate dodecahydrate, 0.24 mg / mL potassium dihydrogen phosphate, 0.2 mg / mL potassium chloride, 8.0 mg / mL sodium chloride and water, wherein mg / mL is the ratio of the mass of each component in the epiriprazole laurate suspension to the volume of water in the epiriprazole laurate suspension; Wherein, the D of the epiriprazole laurate granules is 10 0.93μm, D 50 2.21 μm, D 90 is 6.00 μm, and the particle size distribution span is 2.3; (3) The epiriprazole laurate suspension is composed of the following components: 223.45 mg / mL epiriprazole laurate particles, 10 mg / mL Tween 20, 30 mg / mL polyethylene glycol 4000, 10 mg / mL poloxamer 188, 3.63 mg / mL disodium hydrogen phosphate dodecahydrate, 0.24 mg / mL potassium dihydrogen phosphate, 0.2 mg / mL potassium chloride, 8.0 mg / mL sodium chloride and water, wherein mg / mL is the ratio of the mass of each component in the epiriprazole laurate suspension to the volume of water in the epiriprazole laurate suspension; Wherein, the D of the epiriprazole laurate granules is 10 1.4μm, D 50 3.6μm, D 90 is 10.5 μm, and the particle size distribution span is 2.5; (4) The epiriprazole laurate suspension is composed of the following components: 75 mg / mL epiriprazole laurate particles, 5 mg / mL Tween 20, 15 mg / mL polyethylene glycol 4000, 3.63 mg / mL disodium hydrogen phosphate dodecahydrate, 0.24 mg / mL potassium dihydrogen phosphate, 0.2 mg / mL potassium chloride, 8.0 mg / mL sodium chloride and water, wherein mg / mL is the ratio of the mass of each component in the epiriprazole laurate suspension to the volume of water in the epiriprazole laurate suspension; Wherein, the D of the epiriprazole laurate granules is 10 2.0μm, D 50 4.1μm, D 90 is 7.0 μm, and the particle size distribution span is 1.2; (5) The epiriprazole laurate suspension is composed of the following components: 75 mg / mL epiriprazole laurate particles, 5 mg / mL Tween 20, 15 mg / mL polyethylene glycol 4000, 3.63 mg / mL disodium hydrogen phosphate dodecahydrate, 0.24 mg / mL potassium dihydrogen phosphate, 0.2 mg / mL potassium chloride, 8.0 mg / mL sodium chloride and water, wherein mg / mL is the ratio of the mass of each component in the epiriprazole laurate suspension to the volume of water in the epiriprazole laurate suspension; Wherein, the D of the epiriprazole laurate granules is 10 3.3μm, D 50 6.0μm, D 90 is 10.4 μm, and the particle size distribution span is 1.2; (6) The epiriprazole laurate suspension is composed of the following components: 200 mg / mL epiriprazole laurate particles, 5 mg / mL Tween 20, 30 mg / mL polyethylene glycol 4000, 10 mg / mL poloxamer 188, 3.63 mg / mL disodium hydrogen phosphate dodecahydrate, 0.24 mg / mL potassium dihydrogen phosphate, 0.2 mg / mL potassium chloride, 8.0 mg / mL sodium chloride and water, wherein mg / mL is the ratio of the mass of each component in the epiriprazole laurate suspension to the volume of water in the epiriprazole laurate suspension; Wherein, the D of the epiriprazole laurate granules is 10 1.0μm, D 50 1.8μm, D 90 is 3.1 μm, and the particle size distribution span is 1.2; (7) The epiriprazole laurate suspension is composed of the following components: 200 mg / mL epiriprazole laurate particles, 5 mg / mL Tween 20, 30 mg / mL polyethylene glycol 4000, 10 mg / mL poloxamer 188, 3.63 mg / mL disodium hydrogen phosphate dodecahydrate, 0.24 mg / mL potassium dihydrogen phosphate, 0.2 mg / mL potassium chloride, 8.0 mg / mL sodium chloride and water, wherein mg / mL is the ratio of the mass of each component in the epiriprazole laurate suspension to the volume of water in the epiriprazole laurate suspension; Wherein, the D of the epiriprazole laurate granules is 10 1.3μm, D 50 2.5μm, D 90 The particle size distribution span is 1.
3.
8. A method for preparing an epiriprazole laurate suspension, characterized in that: It includes the following steps: The primary particles of epiridol laurate are mixed with the mixture A, and an intermediate suspension is obtained by ultrasonic stirring and / or shearing, and the intermediate suspension is prepared by a microfluidization high-pressure homogenization method to obtain an epiridol laurate suspension; Wherein, mixture A is composed of particle stabilizer, buffer salt, isotonicity regulator and water.
9. The method for preparing the suspension of epiriprazole laurate according to claim 8, characterized in that: The preparation method of the epiriprazole laurate suspension satisfies one or more of the following conditions: (1) The primary particles of epiriprazole laurate are prepared by at least one of recrystallization, grinding and sieving, preferably by recrystallization; the solvent of the recrystallization is preferably acetone; (2) the primary particles of epiprazole laurate are in the form of an amorphous substance or a crystalline form of epiprazole laurate, preferably epiprazole laurate crystalline form A; (3) The average particle diameter of the primary particles of epiriprazole laurate is preferably 0.1 to 50 μm, for example 30.4 μm; (4) The dosage of the primary particles of epiriprazole laurate is 10-1000 mg / mL, preferably 50-250 mg / mL, for example 75 mg / mL, 200 mg / mL or 223.45 mg / mL; (5) The particle stabilizer is one or more of poloxamer, polyvinyl pyrrolidone, hydroxypropyl methylcellulose, Tween and polyethylene glycol; the polyethylene glycol is preferably polyethylene glycol 4000; the poloxamer is preferably poloxamer 188 or poloxamer 407; the hydroxypropyl methylcellulose is preferably hydroxypropyl methylcellulose E3 or hydroxypropyl methylcellulose E5; the Tween is preferably Tween 80 or Tween 20; the particle stabilizer is more preferably Tween 20 and polyethylene glycol 4000, or, poloxamer 188, Tween 20 and polyethylene glycol 4000; (6) The amount of the particle stabilizer is 10-60 mg / mL, for example 20 mg / mL, 40 mg / mL, 45 mg / mL or 50 mg / mL; (7) The buffer salt is one or more of disodium hydrogen phosphate, disodium hydrogen phosphate dodecahydrate, dipotassium hydrogen phosphate, dipotassium hydrogen phosphate trihydrate, potassium dihydrogen phosphate and sodium dihydrogen phosphate, such as disodium hydrogen phosphate dodecahydrate and potassium dihydrogen phosphate; (8) The amount of the buffer salt is 3-5 mg / mL, for example 3.87 mg / mL; (9) The isotonicity adjusting agent is sodium chloride and potassium chloride; (10) The dosage of the isotonicity adjusting agent is 7-10 mg / mL, for example 8.2 mg / mL; (11) The water is water for injection; (12) the mixing is carried out under ultrasound; (13) The shearing speed is 5000-15000 rpm; (14) The shearing time is 3-10 minutes; (15) In the microfluidizer high pressure homogenization method, the homogenization pressure is 2000-25000 psi; (16) In the microfluidizer high pressure homogenization method, the homogenization times are 5-25 times; (17) In the micro-jet high-pressure homogenization method, the aperture of the nozzle is 10-30 mm.
10. The method for preparing the suspension of epiriprazole laurate according to claim 8, characterized in that: The preparation method of the epiriprazole laurate suspension satisfies one or more of the following conditions: (1) When the particle stabilizers are Tween 20 and polyethylene glycol 4000, the amount of Tween 20 is 5-10 mg / mL; the amount of polyethylene glycol 4000 is 15-30 mg / mL; (2) When the particle stabilizers are poloxamer 188, Tween 20 and polyethylene glycol 4000, the amount of Tween 20 is 5-10 mg / mL; the amount of polyethylene glycol 4000 is 15-30 mg / mL; the amount of poloxamer 188 is 10 mg / mL; (3) When the buffer salt is disodium hydrogen phosphate dodecahydrate and potassium dihydrogen phosphate, the amount of the disodium hydrogen phosphate dodecahydrate is 3-4 mg / mL, for example, 3.63 mg / mL; the amount of the potassium dihydrogen phosphate is 0.1-1 mg / mL, for example, 0.24 mg / mL; (4) When the isotonicity adjusting agents are sodium chloride and potassium chloride, the amount of potassium chloride is 0.1-0.3 mg / mL, for example, 0.2 mg / mL; the amount of sodium chloride is 7.0-9.0 mg / mL, for example, 8.0 mg / mL; (5) The shearing speed is 10000 rpm; (6) The shearing time is 5 minutes; (7) In the microfluidizer high pressure homogenization method, the homogenization pressure is 5000psi, 8000psi, 10000psi, 15000psi, 20000psi or 24000psi; (8) In the microfluidizer high pressure homogenization method, the homogenization times are 8 times, 10 times, 12 times, 15 times or 20 times; (9) In the micro-jet high-pressure homogenization method, the aperture of the nozzle is 13-25 mm.
11. The method for preparing the epiriprazole laurate suspension according to claim 8, characterized in that: The mixture A is composed of the following components: 10-60 mg / mL of a particle stabilizer, 3-5 mg / mL of a buffer salt, 7-10 mg / mL of an isotonicity regulator, and water, wherein mg / mL is the ratio of the mass of each component in the mixture A to the volume of water in the mixture A; Preferably, the mixture A is composed of the following components: 5-10 mg / mL Tween 20, 15-30 mg / mL polyethylene glycol 4000, 0-10 mg / mL poloxamer 188, 3.63 mg / mL disodium hydrogen phosphate dodecahydrate, 0.24 mg / mL potassium dihydrogen phosphate, 0.2 mg / mL potassium chloride, 8.0 mg / mL sodium chloride and water, wherein mg / mL is the ratio of the mass of each component in the mixture A to the volume of water in the mixture A.
12. An epiriprazole laurate suspension, characterized in that: It is prepared by the preparation method described in any one of claims 8 to 11.
13. Use of the suspension of epiliprazole laurate according to any one of claims 1 to 7 or 12 in the preparation of a drug for treating or preventing a disease, wherein the disease is schizophrenia, bipolar disorder or relapse of depression.
Citation Information
Patent Citations
Piperazine-substituted benzothiophene derivatives as antipsychotic agents
CN103781783A
Injectable formulation
CN104363912A
